vs

Side-by-side financial comparison of OCULAR THERAPEUTIX, INC (OCUL) and SuperCom Ltd (SPCB). Click either name above to swap in a different company.

SuperCom Ltd is the larger business by last-quarter revenue ($14.2M vs $13.3M, roughly 1.1× OCULAR THERAPEUTIX, INC). SuperCom Ltd runs the higher net margin — 37.5% vs -488.0%, a 525.5% gap on every dollar of revenue. On growth, SuperCom Ltd posted the faster year-over-year revenue change (-1.5% vs -22.4%). SuperCom Ltd produced more free cash flow last quarter ($-3.6M vs $-57.1M).

Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.

Super.com is a technology company headquartered in San Francisco and co-founded by Hussein Fazal and Henry Shi. The company provides financial services, including reward programs and travel bookings.

OCUL vs SPCB — Head-to-Head

Bigger by revenue
SPCB
SPCB
1.1× larger
SPCB
$14.2M
$13.3M
OCUL
Growing faster (revenue YoY)
SPCB
SPCB
+21.0% gap
SPCB
-1.5%
-22.4%
OCUL
Higher net margin
SPCB
SPCB
525.5% more per $
SPCB
37.5%
-488.0%
OCUL
More free cash flow
SPCB
SPCB
$53.5M more FCF
SPCB
$-3.6M
$-57.1M
OCUL

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
OCUL
OCUL
SPCB
SPCB
Revenue
$13.3M
$14.2M
Net Profit
$-64.7M
$5.3M
Gross Margin
88.0%
61.2%
Operating Margin
-526.5%
16.3%
Net Margin
-488.0%
37.5%
Revenue YoY
-22.4%
-1.5%
Net Profit YoY
-33.6%
79.5%
EPS (diluted)
$-0.27
$1.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OCUL
OCUL
SPCB
SPCB
Q4 25
$13.3M
Q3 25
$14.5M
Q2 25
$13.5M
$14.2M
Q1 25
$10.7M
Q4 24
$17.1M
Q3 24
$15.4M
Q2 24
$16.4M
$14.4M
Q1 24
$14.8M
Net Profit
OCUL
OCUL
SPCB
SPCB
Q4 25
$-64.7M
Q3 25
$-69.4M
Q2 25
$-67.8M
$5.3M
Q1 25
$-64.1M
Q4 24
$-48.4M
Q3 24
$-36.5M
Q2 24
$-43.8M
$3.0M
Q1 24
$-64.8M
Gross Margin
OCUL
OCUL
SPCB
SPCB
Q4 25
88.0%
Q3 25
87.8%
Q2 25
85.6%
61.2%
Q1 25
88.2%
Q4 24
92.8%
Q3 24
89.9%
Q2 24
90.8%
52.3%
Q1 24
91.0%
Operating Margin
OCUL
OCUL
SPCB
SPCB
Q4 25
-526.5%
Q3 25
-472.3%
Q2 25
-502.6%
16.3%
Q1 25
-597.5%
Q4 24
-296.1%
Q3 24
-298.2%
Q2 24
-265.1%
7.7%
Q1 24
-214.0%
Net Margin
OCUL
OCUL
SPCB
SPCB
Q4 25
-488.0%
Q3 25
-477.3%
Q2 25
-503.9%
37.5%
Q1 25
-598.7%
Q4 24
-283.3%
Q3 24
-236.6%
Q2 24
-266.3%
20.6%
Q1 24
-438.9%
EPS (diluted)
OCUL
OCUL
SPCB
SPCB
Q4 25
$-0.27
Q3 25
$-0.38
Q2 25
$-0.39
$1.32
Q1 25
$-0.38
Q4 24
$-0.25
Q3 24
$-0.22
Q2 24
$-0.26
$1.19
Q1 24
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OCUL
OCUL
SPCB
SPCB
Cash + ST InvestmentsLiquidity on hand
$737.1M
$15.0M
Total DebtLower is stronger
$23.6M
Stockholders' EquityBook value
$654.3M
$37.3M
Total Assets
$808.1M
$65.5M
Debt / EquityLower = less leverage
0.63×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OCUL
OCUL
SPCB
SPCB
Q4 25
$737.1M
Q3 25
$344.8M
Q2 25
$391.1M
$15.0M
Q1 25
$349.7M
Q4 24
$392.1M
Q3 24
$427.2M
Q2 24
$459.7M
$5.7M
Q1 24
$482.9M
Total Debt
OCUL
OCUL
SPCB
SPCB
Q4 25
Q3 25
Q2 25
$23.6M
Q1 25
Q4 24
Q3 24
Q2 24
$29.2M
Q1 24
Stockholders' Equity
OCUL
OCUL
SPCB
SPCB
Q4 25
$654.3M
Q3 25
$258.2M
Q2 25
$305.9M
$37.3M
Q1 25
$265.9M
Q4 24
$315.3M
Q3 24
$352.0M
Q2 24
$377.7M
$13.8M
Q1 24
$408.0M
Total Assets
OCUL
OCUL
SPCB
SPCB
Q4 25
$808.1M
Q3 25
$410.9M
Q2 25
$451.3M
$65.5M
Q1 25
$405.9M
Q4 24
$457.9M
Q3 24
$490.4M
Q2 24
$517.1M
$49.6M
Q1 24
$538.9M
Debt / Equity
OCUL
OCUL
SPCB
SPCB
Q4 25
Q3 25
Q2 25
0.63×
Q1 25
Q4 24
Q3 24
Q2 24
2.11×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OCUL
OCUL
SPCB
SPCB
Operating Cash FlowLast quarter
$-54.2M
$-2.2M
Free Cash FlowOCF − Capex
$-57.1M
$-3.6M
FCF MarginFCF / Revenue
-430.9%
-25.3%
Capex IntensityCapex / Revenue
21.4%
10.0%
Cash ConversionOCF / Net Profit
-0.41×
TTM Free Cash FlowTrailing 4 quarters
$-216.9M
$-14.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OCUL
OCUL
SPCB
SPCB
Q4 25
$-54.2M
Q3 25
$-50.7M
Q2 25
$-55.2M
$-2.2M
Q1 25
$-44.7M
Q4 24
$-39.4M
Q3 24
$-36.6M
Q2 24
$-24.8M
$-950.0K
Q1 24
$-33.9M
Free Cash Flow
OCUL
OCUL
SPCB
SPCB
Q4 25
$-57.1M
Q3 25
$-56.7M
Q2 25
$-56.5M
$-3.6M
Q1 25
$-46.6M
Q4 24
$-39.6M
Q3 24
$-36.6M
Q2 24
$-25.5M
$-1.6M
Q1 24
$-34.1M
FCF Margin
OCUL
OCUL
SPCB
SPCB
Q4 25
-430.9%
Q3 25
-390.0%
Q2 25
-419.7%
-25.3%
Q1 25
-435.6%
Q4 24
-232.0%
Q3 24
-237.6%
Q2 24
-155.4%
-10.8%
Q1 24
-231.1%
Capex Intensity
OCUL
OCUL
SPCB
SPCB
Q4 25
21.4%
Q3 25
41.2%
Q2 25
9.3%
10.0%
Q1 25
18.1%
Q4 24
1.2%
Q3 24
0.6%
Q2 24
4.5%
4.2%
Q1 24
1.7%
Cash Conversion
OCUL
OCUL
SPCB
SPCB
Q4 25
Q3 25
Q2 25
-0.41×
Q1 25
Q4 24
Q3 24
Q2 24
-0.32×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons